The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works

Control of Regulatory T Cell Development by the Transcription Factor <i>Foxp3</i>

Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187 · see citing works

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745 · see citing works

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · see citing works

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · see citing works

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works

PD-1 and Its Ligands in Tolerance and Immunity

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works

Regulatory T Cells and Immune Tolerance

Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,357 · see citing works

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · see citing works

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025 · see citing works

The immune contexture in human tumours: impact on clinical outcome

Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · see citing works

Nivolumab plus Ipilimumab in Advanced Melanoma

Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1× · see citing works

The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer

Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,090 · see citing works

T cell exhaustion

Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 2× · see citing works

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,564 · see citing works

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,373 · see citing works

Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259 · see citing works

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,204 · see citing works

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · see citing works

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955 · see citing works

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · see citing works

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781 · see citing works

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in <i>Ctla-4</i>

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · see citing works

Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor

Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · see citing works

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680 · see citing works

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676 · see citing works

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496 · see citing works

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Powles, T. B., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Joaquim Bellmunt, B., Burris, H. A., Petrylak, D. P., Teng, S.-L. M., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,383 · see citing works

The PD‐1 pathway in tolerance and autoimmunity

Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300 · see citing works

Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3

Fontenot, J. D., Rasmussen, J. P., Williams, L. M., Dooley, J., Farr, A. G., & Rudensky, A. Y. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.016 · Cited by 2,254 · see citing works

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222 · see citing works

Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis

Chang, C.-H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., Huang, S. C.-C., van der Windt, G. J. W., Blagih, J., Qiu, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.016 · Cited by 2,204 · see citing works

Control of Viremia in Simian Immunodeficiency Virus Infection by CD8 + Lymphocytes

Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton, M. A., Rácz, P., Tenner‐Racz, K., Dalesandro, M. R., Scallon, B. J., et al. (1999) · Science · doi:10.1126/science.283.5403.857 · Cited by 2,167 · see citing works

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · see citing works

Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets

Michalek, R. D., Gerriets, V. A., Jacobs, S. R., Macintyre, A. N., MacIver, N. J., Mason, E. F., Sullivan, S. A., Nichols, A. G., & Rathmell, J. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003613 · Cited by 2,091 · see citing works

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072 · see citing works

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062 · see citing works

CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931 · see citing works

Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice

Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868 · see citing works

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774 · see citing works

Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766 · see citing works

A Theory of Self-Nonself Discrimination

Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,755 · see citing works

Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment

Wherry, E. J., Blattman, J. N., Murali‐Krishna, K., der Most, R. G. V., & Ahmed, R. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4911-4927.2003 · Cited by 1,599 · see citing works

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589 · see citing works

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,580 · see citing works

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

Pearce, E. L., Walsh, M. C., Cejas, P. J., Harms, G. M., Shen, H., Wang, L.-S., Jones, R. G., & Choi, Y. (2009) · Nature · doi:10.1038/nature08097 · Cited by 1,559 · see citing works

SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27

Carrano, A. C., Eytan, E., Hershko, A., & Pagano, M. (1999) · Nature Cell Biology · doi:10.1038/12013 · Cited by 1,544 · see citing works

The CD28 Signaling Pathway Regulates Glucose Metabolism

Frauwirth, K. A., Riley, J. L., Harris, M. H., Parry, R. V., Rathmell, J. C., Plas, D. R., Elstrom, R. L., June, C. H., & Thompson, C. B. (2002) · Immunity · doi:10.1016/s1074-7613(02)00323-0 · Cited by 1,475 · see citing works

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415 · see citing works

Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques

Jin, X., Bauer, D. E., Tuttleton, S., Lewin, S. R., Gettie, A., Blanchard, J., Irwin, C. E., Safrit, J. T., Mittler, J. E., Weinberger, L. S., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.6.991 · Cited by 1,405 · see citing works

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 ⁺ T lymphocytes are prognostic factors of human ovarian cancer

Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378 · see citing works

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,341 · see citing works

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

Green, M. R., Monti, S., Rodig, S. J., Juszczyński, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D. S., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,307 · see citing works

PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma

Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258 · see citing works

The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling

Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249 · see citing works

SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation

Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246 · see citing works

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

Patsoukis, N., Bardhan, K., Chatterjee, P., Sari, D., Liu, B., Bell, L. N., Karoly, E. D., Freeman, G. J., Petkova, V., Seth, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms7692 · Cited by 1,210 · see citing works

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3708 · Cited by 1,180 · see citing works

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · see citing works

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T. F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0703 · Cited by 1,074 · see citing works

Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation

Salomon, B. L., & Bluestone, J. A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.225 · Cited by 1,005 · see citing works

CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy

Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.565 · Cited by 1,000 · see citing works

TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells

Marie, J. C., Letterio, J. J., Gavin, M. A., & Rudensky, A. Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042276 · Cited by 986 · see citing works

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

Brown, J. A., Dorfman, D. M., Ma, F.-R., Sullivan, E. L., Munoz, O., Wood, C. R., Greenfield, E. A., & Freeman, G. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1257 · Cited by 968 · see citing works

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

Hodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30366-7 · Cited by 968 · see citing works

Expression of Programmed Death 1 Ligands by Murine T Cells and APC

Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D. M., Okumura, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5538 · Cited by 950 · see citing works

REGULATION OF IMMUNE RESPONSES THROUGH INHIBITORY RECEPTORS

Long, E. O. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.875 · Cited by 943 · see citing works

Progenitor and Terminal Subsets of CD8 + T Cells Cooperate to Contain Chronic Viral Infection

Paley, M., Kroy, D. C., Odorizzi, P. M., Johnnidis, J. B., Dolfi, D. V., Barnett, B. E., Bikoff, E. K., Robertson, E. J., Lauer, G. M., Reiner, S. L., et al. (2012) · Science · doi:10.1126/science.1229620 · Cited by 903 · see citing works

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

Kuang, D., Zhao, Q., Peng, C., Xu, J., Zhang, J., Wu, C. Y., & Zheng, L. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20082173 · Cited by 897 · see citing works

PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection

Petrovas, C., Casazza, J. P., Brenchley, J. M., Price, D. A., Gostick, E., Adams, W. C., Precopio, M. L., Schacker, T., Roederer, M., Douek, D. C., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061496 · Cited by 889 · see citing works

Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889 · see citing works

The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures

Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.008 · Cited by 861 · see citing works

PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine

Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231486598 · Cited by 849 · see citing works

The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice

Ansari, M. J., Salama, A. D., Chitnis, T., Smith, R. N., Yagita∥, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 806 · see citing works

Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796 · see citing works

PD‐1 inhibits T‐cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ

Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791 · see citing works

PD-1 signaling in primary T cells

Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778 · see citing works

Phosphorylation of the PTEN Tail Regulates Protein Stability and Function

Vázquez, F., Ramaswamy, S., Nakamura, N., & Sellers, W. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5010-5018.2000 · Cited by 777 · see citing works

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776 · see citing works

The AKT–mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells

Haxhinasto, S., Mathis, D., & Benoist, C. (2008) · Journal of Experimental Medicine · doi:10.1084/jem.20071477 · Cited by 775 · see citing works

A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans

Prokunina‐Olsson, L., Castillejo-López, C., Oberg, F. G., Gunnarsson, I., Berg, L., Magnusson, V., Brookes, A. J., Tentler, D., Kristjansdóttir, H., Gröndal, G., et al. (2002) · Nature Genetics · doi:10.1038/ng1020 · Cited by 770 · see citing works

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M. E., Wang, H. Y., Wysocka, M., Cheng, M. M., Ruggeri, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 731 · see citing works

In Vivo Instruction of Suppressor Commitment in Naive T Cells

Apostolou, I., & von Boehmer, H. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040249 · Cited by 728 · see citing works

TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling

Becker, C., Fantini, M. C., Schramm, C., Lehr, H. A., Wirtz, S., Nikolaev, A., Burg, J., Strand, S., Kiesslich, R., Huber, S., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.020 · Cited by 726 · see citing works

RasGRP, a Ras Guanyl Nucleotide- Releasing Protein with Calcium- and Diacylglycerol-Binding Motifs

Ebinu, J. O., Bottorff, D. A., Chan, E. Y. W., Stang, S. L., Dunn, R. J., & Stone, J. C. (1998) · Science · doi:10.1126/science.280.5366.1082 · Cited by 675 · see citing works

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

Armand, P. A., Shipp, M. A., Ribrag, V., Michot, J., Zinzani, P. L., Kuruvilla, J. G., Snyder, E., Ricart, A. D., Balakumaran, A., Rose, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3467 · Cited by 670 · see citing works

Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T., & TOKURA, Y. (2010) · Cancer · doi:10.1002/cncr.24899 · Cited by 668 · see citing works

Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses

Liang, S. C., Latchman, Y. E., Buhlmann, J. E., Tomczak, M. F., Horwitz, B. H., Freeman, G. J., & Sharpe, A. H. (2003) · European Journal of Immunology · doi:10.1002/eji.200324228 · Cited by 635 · see citing works

The Tumor Suppressor PTEN Is Phosphorylated by the Protein Kinase CK2 at Its C Terminus

Torres, J., & Pulido, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009134200 · Cited by 630 · see citing works

Cytokine Stimulation Promotes Glucose Uptake via Phosphatidylinositol-3 Kinase/Akt Regulation of Glut1 Activity and Trafficking

Wieman, H. L., Wofford, J. A., & Rathmell, J. C. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-07-0593 · Cited by 593 · see citing works

PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion

Urbani, S., Amadei, B., Tola, D., Massari, M., Schivazappa, S., Missale, G., & Ferrari, C. I. (2006) · Journal of Virology · doi:10.1128/jvi.01177-06 · Cited by 588 · see citing works

Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway

Liu, J., Hamrouni, A., Wołowiec, D., Coiteux, V., Kuliczkowski, K., Hétuin, D., Saudemont, A., & Quesnel, B. (2007) · Blood · doi:10.1182/blood-2006-10-051482 · Cited by 580 · see citing works

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

Lipson, E. J., Sharfman, W. H., Drake, C. G., WOLLNER, I. S., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., Chen, L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2625 · Cited by 546 · see citing works

Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomão, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm0902-1039c · Cited by 545 · see citing works

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4802 · Cited by 535 · see citing works

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Westin, J. R., Chu, F., Zhang, M., Fayad, L., Kwak, L. W., Fowler, N. H., Romaguera, J. E., Hagemeister, F. B., Fanale, M. A., Samaniego, F., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70551-5 · Cited by 529 · see citing works

Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation

Patsoukis, N., Brown, J., Petkova, V., Liu, F., Li, L., & Boussiotis, V. A. (2012) · Science Signaling · doi:10.1126/scisignal.2002796 · Cited by 529 · see citing works

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

Azuma, T., Yao, S., Zhu, G., Flies, A. S., Flies, S. J., & Chen, L. (2008) · Blood · doi:10.1182/blood-2007-11-123141 · Cited by 528 · see citing works

Cutting Edge: IL-2 Is Essential for TGF-β-Mediated Induction of Foxp3+ T Regulatory Cells

Davidson, T. S., DiPaolo, R. J., Andersson, J., & Shevach, E. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4022 · Cited by 520 · see citing works

Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes

Joffre, O. P., Santolaria, T., Calise, D., Saati, T. A., Hudrisier, D., Romagnoli, P., & van Meerwijk, J. P. M. (2007) · Nature Medicine · doi:10.1038/nm1688 · Cited by 514 · see citing works

The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands

Kinter, A. L., Godbout, E. J., McNally, J. P., Sereti, I., Roby, G. A., O’Shea, M. A., & Fauci, A. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6738 · Cited by 513 · see citing works

Cyclin-dependent kinases regulate the antiproliferative function of Smads

Matsuura, I., Denissova, N. G., Wang, G., He, D., Long, J., & Liu, F. (2004) · Nature · doi:10.1038/nature02650 · Cited by 506 · see citing works

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

Hammers, H. J., Plimack, E. R., Infante, J. R., Rini, B. I., McDermott, D. F., Lewis, L. D., Voss, M. H., Sharma, P., Pal, S. K., Razak, A. R. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1985 · Cited by 504 · see citing works

Antigen-independent memory CD8 T cells do not develop during chronic viral infection

Wherry, E. J., Barber, D. L., Kaech, S. M., Blattman, J. N., & Ahmed, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407192101 · Cited by 495 · see citing works

Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

Wu, C., Zhu, Y., Jiang, J., Zhao, J., Zhang, X., & Xu, N. (2006) · Acta Histochemica · doi:10.1016/j.acthis.2006.01.003 · Cited by 492 · see citing works

Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection

Kao, C., Oestreich, K. J., Paley, M., Crawford, A., Angelosanto, J., Ali, M.-A. A., Intlekofer, A. M., Boss, J. M., Reiner, S. L., Weinmann, A. S., et al. (2011) · Nature Immunology · doi:10.1038/ni.2046 · Cited by 484 · see citing works

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., & Ueda, S. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0266-z · Cited by 473 · see citing works

In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability

Rathmell, J. C., Heiden, M. G. V., Harris, M. H., Frauwirth, K. A., & Thompson, C. B. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00066-6 · Cited by 467 · see citing works

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

Lin, D. Y.-W., Tanaka, Y., Iwasaki, M., Gittis, A. G., Su, H.-P., Mikami, B., Okazaki, T., Honjo, T., Minato, N., & Garboczi, D. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712278105 · Cited by 465 · see citing works

Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274)

Lee, S. J., Jang, B., Lee, S.-W., Yang, Y., Suh, S., Park, Y.-M., Oh, S., Shin, J., Yao, S., Chen, L., et al. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.093 · Cited by 446 · see citing works

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

Armand, P. A., Nagler, A., Weller, E. A., Devine, S. M., Avigan, D., Chen, Y., Kaminski, M. S., Holland, H. K., Winter, J. N., Mason, J. R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3685 · Cited by 440 · see citing works

A critical role for the programmed death ligand 1 in fetomaternal tolerance

Guleria, I., Khosroshahi, A., Ansari, M. J., Habicht, A., Azuma, M., Yagita∥, H., Noelle, R. J., Coyle, A. J., Mellor, A. L., Khoury, S. J., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050019 · Cited by 439 · see citing works

Establishment of NOD- Pdcd1 -/- mice as an efficient animal model of type I diabetes

Wang, J., Yoshida, T., Nakaki, F., Hiai, H., Okazaki, T., & Honjo, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505497102 · Cited by 436 · see citing works

The when and wheres of CDC25 phosphatases

Boutros, R., Dozier, C., & Ducommun, B. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.02.003 · Cited by 417 · see citing works

NFATc1 Regulates PD-1 Expression upon T Cell Activation

Oestreich, K. J., Yoon, H., Ahmed, R., & Boss, J. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4832 · Cited by 416 · see citing works

The Small Gtpase, Rap1, Mediates Cd31-Induced Integrin Adhesion

Reedquist, K. A., Ross, E. A., Koop, E. A., Wolthuis, R. M. F., Zwartkruis, F. J. T., van Kooyk, Y., Salmon, M., Buckley, C. D., & Bos, J. L. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.148.6.1151 · Cited by 415 · see citing works

Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1

Zhang, X., Schwartz, J.-C. D., Guo, X., Bhatia, S., Cao, E., Chen, L., Zhang, Z., Edidin, M. A., Nathenson, S. G., & Almo, S. C. (2004) · Immunity · doi:10.1016/s1074-7613(04)00051-2 · Cited by 411 · see citing works

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

Zhang, L., Gajewski, T. F., & Kline, J. P. (2009) · Blood · doi:10.1182/blood-2009-03-206672 · Cited by 409 · see citing works

Phospholipase Cγ activates Ras on the Golgi apparatus by means of RasGRP1

Bivona, T. G., de Castro, I. P., Ahearn, I. M., Grana, T. M., Chiu, V. K., Lockyer, P. J., Cullen, P. J., Pellicer, À., Cox, A. D., & Philips, M. R. (2003) · Nature · doi:10.1038/nature01806 · Cited by 401 · see citing works

Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras.

Bennett, A. M., Tang, T. L., Sugimoto, S., Walsh, C. T., & Neel, B. G. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7335 · Cited by 397 · see citing works

Direct Regulation of ZAP-70 by SHP-1 in T Cell Antigen Receptor Signaling

Plas, D. R., Johnson, R. R., Pingel, J. T., Matthews, R. J., Dalton, M., Roy, G., Chan, A. C., & Thomas, M. L. (1996) · Science · doi:10.1126/science.272.5265.1173 · Cited by 392 · see citing works

A two-step, two-signal model for the primary activation of precursor helper T cells

Bretscher, P. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.185 · Cited by 389 · see citing works

618: Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target

Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2005) · The Journal of Urology · doi:10.1016/s0022-5347(18)34858-4 · Cited by 386 · see citing works

The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic Infection

Staron, M. M., Gray, S. M., Marshall, H. D., Parish, I. A., Chen, J. H., Perry, C. J., Cui, G., Li, M. O., & Kaech, S. M. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.013 · Cited by 384 · see citing works

Regulation of T Lymphocyte Metabolism

Frauwirth, K. A., & Thompson, C. B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.8.4661 · Cited by 371 · see citing works

CD28, CTLA‐4 and their ligands: who does what and to whom?

Sansom, D. M. (2000) · Immunology · doi:10.1046/j.1365-2567.2000.00121.x · Cited by 362 · see citing works

CD8 T cell dysfunction during chronic viral infection

Shin, H., & Wherry, E. J. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.06.004 · Cited by 346 · see citing works

IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity

Terawaki, S., Chikuma, S., Shibayama, S., Hayashi, T., Yoshida, T., Okazaki, T., & Honjo, T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003208 · Cited by 344 · see citing works

Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin

Strauss, L., Whiteside, T. L., Knights, A. J., Bergmann, C., Knuth, A. K., & Zippelius, A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.320 · Cited by 335 · see citing works

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies

Philips, G. K., & Atkins, M. B. (2014) · International Immunology · doi:10.1093/intimm/dxu095 · Cited by 335 · see citing works

Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism

Blazar, B. R., Carreno, B. M., Panoskaltsis‐Mortari, A., Carter, L., Iwai, Y., Yagita∥, H., Nishimura, H., & Taylor, P. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1272 · Cited by 330 · see citing works

RasGRP links T-cell receptor signaling to Ras

Ebinu, J. O., Stang, S. L., Teixeira, C., Bottorff, D. A., Hooton, J. W. L., Blumberg, P. M., Barry, M. K., Bleakley, R. C., Ostergaard, H. L., & Stone, J. C. (2000) · Blood · doi:10.1182/blood.v95.10.3199 · Cited by 326 · see citing works

T cell anergy and costimulation

Appleman, L. J., & Boussiotis, V. A. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00009.x · Cited by 306 · see citing works

T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection

Buggert, M., Tauriainen, J., Yamamoto, T., Frederiksen, J., Ivarsson, M. A., Michaëlsson, J., Lund, O., Hejdeman, B., Jansson, M., Sönnerborg, A. B., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004251 · Cited by 293 · see citing works

The Tyrosine Phosphatase SHP-2 Is Required for Sustained Activation of Extracellular Signal-Regulated Kinase and Epithelial Morphogenesis Downstream from the Met Receptor Tyrosine Kinase

Maroun, C. R., Naujokas, M. A., Holgado-Madruga, M., Wong, A. J., & Park, M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.22.8513-8525.2000 · Cited by 286 · see citing works

Cancer immunology—analysis of host and tumor factors for personalized medicine

Ogino, S., Galon, J., Fuchs, C. S., & Dranoff, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.122 · Cited by 284 · see citing works

Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses

Bennett, F., Luxenberg, D. P., Ling, V., Wang, I., Marquette, K., Lowe, D., Khan, N., Veldman, G. M., Jacobs, K. A., Valge-archer, V. E., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.711 · Cited by 283 · see citing works

Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells

Eppihimer, M., Gunn, J., Freeman, G., Greenfield, E., Chernova, T., Erickson, J., & Leonard, J. (2002) · Microcirculation · doi:10.1080/713774061 · Cited by 272 · see citing works

PD-1 deficiency results in the development of fatal myocarditis in MRL mice

Wang, J., Okazaki, I., Yoshida, T., Chikuma, S., Kato, Y., Nakaki, F., Hiai, H., Honjo, T., & Okazaki, T. (2010) · International Immunology · doi:10.1093/intimm/dxq026 · Cited by 267 · see citing works

Developmentally regulated expression of the PD-1 protein on the surface of double-negative(CD4–CD8–) thymocytes

Nishimura, H., Agata, Y., Kawasaki, A., Sato, M., Imamura, S., Minato, N., Yagita∥, H., Nakano, T., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.773 · Cited by 261 · see citing works

B7-H1 (Programmed Death-1 Ligand) on Dendritic Cells Is Involved in the Induction and Maintenance of T Cell Anergy

Selenko-Gebauer, N., Majdic, O., Szekeres, A., Höfler, G., Guthann, E., Korthäuer, U., Zlabinger, G. J., Steinberger, P., Pickl, W. F., Stockinger, H. S. J., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3637 · Cited by 261 · see citing works

The dual-function CD150 receptor subfamily: the viral attraction

Sidorenko, S. P., & Clark, E. A. (2002) · Nature Immunology · doi:10.1038/ni0103-19 · Cited by 255 · see citing works

Identification of the tyrosine phosphatase PTP1C as a B cell antigen receptor-associated protein involved in the regulation of B cell signaling.

Pani, G., Kozlowski, M., Cambier, J. C., Mills, G. B., & Siminovitch, K. A. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.6.2077 · Cited by 251 · see citing works

T‐cell tolerance or function is determined by combinatorial costimulatory signals

Nurieva, R., Thomas, S., Nguyen, T. D., Martín‐Orozco, N., Wang, Y., Murali‐Krishna, K., Yu, X., & Dong, C. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601146 · Cited by 245 · see citing works

Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of treg cells, and enhanced expression of the PD-1 costimulatory pathway

Polanczyk, M. J., Hopke, C., Vandenbark, A. A., & Offner, H. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20881 · Cited by 243 · see citing works

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

Amin, A., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Knox, J. J., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5010 · Cited by 233 · see citing works

A Diacylglycerol-Protein Kinase C-RasGRP1 Pathway Directs Ras Activation upon Antigen Receptor Stimulation of T Cells

Roose, J. P., Mollenauer, M. N., Gupta, V. A., Stone, J. C., & Weiss, A. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.11.4426-4441.2005 · Cited by 210 · see citing works

CTLA-4 and T cell activation

Oosterwegel, M. A., Greenwald, R. J., Mandelbrot, D. A., Lorsbach, R. B., & Sharpe, A. H. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)80047-8 · Cited by 209 · see citing works

Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2

Lázár‐Molnár, E., Yan, Q., Cao, E., Ramagopal, U. A., Nathenson, S. G., & Almo, S. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804453105 · Cited by 208 · see citing works

B7-H1-Induced Apoptosis as a Mechanism of Immune Privilege of Corneal Allografts

Hori, J., Wang, M., Miyashita, M., Tanemoto, K., Takahashi, H., Takemori, T., Okumura, K., Yagita, H., & Azuma, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.5928 · Cited by 208 · see citing works

PD-1 on dendritic cells impedes innate immunity against bacterial infection

Yao, S., Wang, S., Zhu, Y., Luo, L., Zhu, G., Flies, S. J., Xu, H., Ruff, W. E., Broadwater, M., Choi, I.-H., et al. (2009) · Blood · doi:10.1182/blood-2009-02-203141 · Cited by 205 · see citing works

CD28 Costimulation Mediates T Cell Expansion Via IL-2-Independent and IL-2-Dependent Regulation of Cell Cycle Progression

Appleman, L. J., Berezovskaya, A., Grass, I., & Boussiotis, V. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.144 · Cited by 204 · see citing works

CD28 Costimulation Mediates Down-Regulation of p27kip1 and Cell Cycle Progression by Activation of the PI3K/PKB Signaling Pathway in Primary Human T Cells

Appleman, L. J., van Puijenbroek, A. A. F. L., Shu, K. M., Nadler, L. M., & Boussiotis, V. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.6.2729 · Cited by 200 · see citing works

Facilitation of β Selection and Modification of Positive Selection in the Thymus of Pd-1–Deficient Mice

Nishimura, H., Honjo, T., & Minato, N. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.891 · Cited by 192 · see citing works

PD‐L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for VH11/VH12 and phosphatidylcholine binding

Zhong, X., Tumang, J. R., Gao, W., Bai, C., & Rothstein, T. L. (2007) · European Journal of Immunology · doi:10.1002/eji.200737461 · Cited by 190 · see citing works

Different types of V(D)J recombination and end-joining defects in DNA double-strand break repair mutant mammalian cells

Verkaik, N. S., Esveldt, R. E., van Heemst, D., Brüggenwirth, H. T., Hoeijmakers, J. H. J., Zdzienicka, M. Z., & van Gent, D. C. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200203)32:3 · Cited by 189 · see citing works

PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2

Patsoukis, N., Li, L., Sari, D., Petkova, V., & Boussiotis, V. A. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00319-13 · Cited by 187 · see citing works

Lack of SHPTP1 results in src-family kinase hyperactivation and thymocyte hyperresponsiveness.

Lorenz, U. M., Ravichandran, K. S., Burakoff, S. J., & Neel, B. G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9624 · Cited by 171 · see citing works

Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).

Rizvi, N. A., Brahmer, J. R., Ou, S. I., Segal, N. H., Khleif, S. N., Hwu, W., Gutierrez, M. E., Schöffski, P., Hamid, O., Weiss, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8032 · Cited by 159 · see citing works

T-cell Clonal AnergyPreprint

Schwartz, R. H., Mueller, D. L., Jenkins, M. K., & Quill, H. (1989) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1989.054.01.072 · Cited by 159 · see citing works

PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)

Moskowitz, C. H., Ribrag, V., Michot, J., Martinelli, G., Zinzani, P. L., Gutierrez, M. E., Maeyer, G. D., Jacob, A. G., Giallella, K. M., Anderson, J. W., et al. (2014) · Blood · doi:10.1182/blood.v124.21.290.290 · Cited by 153 · see citing works

Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells.

Eppihimer, M. J., Gunn, J., Freeman, G. J., Greenfield, E. A., Chernova, T., Erickson, J., & Leonard, J. P. (2002) · PubMed · doi:10.1038/sj/mn/7800123 · Cited by 149 · see citing works

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

Ribas, A., Hodi, F. S., Kefford, R. F., Hamid, O., DAUD, A. I., Wolchok, J. D., Hwu, W., Gangadhar, T. C., Patnaik, A., Joshua, A. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.18_suppl.lba9000 · Cited by 147 · see citing works

Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

Hammers, H. J., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Razak, A. R. A., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.4504 · Cited by 141 · see citing works

Involvement of SH2-containing Phosphotyrosine Phosphatase Syp in Erythropoietin Receptor Signal Transduction Pathways

Tauchi, T., Feng, G., Shen, R., Hoatlin, M. E., Bagby, G. C., Kabat, D., Lu, L., & Broxmeyer, H. E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.10.5631 · Cited by 139 · see citing works

Cutting Edge: Programed Death (PD) Ligand-1/PD-1 Interaction Is Required for CD8+ T Cell Tolerance to Tissue Antigens

Martín‐Orozco, N., Wang, Y.-H., Yagita∥, H., & Dong, C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8291 · Cited by 138 · see citing works

Notch signaling regulates PD‐1 expression during CD8 + T‐cell activation

Mathieu, M., Cotta‐Grand, N., Daudelin, J., Thébault, P., & Labrecque, N. (2012) · Immunology and Cell Biology · doi:10.1038/icb.2012.53 · Cited by 131 · see citing works

Programmed Death-1 Controls T Cell Survival by Regulating Oxidative Metabolism

Tkachev, V., Goodell, S., Opipari, A. W., Hao, L.-Y., Franchi, L., Glick, G. D., Ferrara, J. L. M., & Byersdorfer, C. A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402180 · Cited by 122 · see citing works

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).

Spira, A. I., Park, K., Mazières, J., Vansteenkiste, J., Rittmeyer, A., Ballinger, M. D., Waterkamp, D., Kowanetz, M., Mokatrin, A., & Fehrenbacher, L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8010 · Cited by 121 · see citing works

TGF-β1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets

Pyzik, M., & Piccirillo, C. A. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1006644 · Cited by 115 · see citing works

PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis

Ding, H., Wu, X., & Gao, W. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.01.005 · Cited by 109 · see citing works

Interferon-sensitive response element (ISRE) is mainly responsible for IFN-α-induced upregulation of programmed death-1 (PD-1) in macrophages

Cho, H.-Y., Lee, S.-W., Seo, S., Choi, I., Choi, I., & Lee, S.-W. (2008) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2008.08.003 · Cited by 102 · see citing works

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).

Cho, D. C., Sosman, J. A., Sznol, M., Gordon, M. S., Hollebecque, A., Hamid, O., McDermott, D. F., Delord, J., Rhee, I. P., Mokatrin, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.4505 · Cited by 97 · see citing works

CD18 Is Required for Optimal Development and Function of CD4+CD25+ T Regulatory Cells

Marski, M., Kandula, S., Turner, J. R., & Abraham, C. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.7889 · Cited by 95 · see citing works

PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection

Watanabe, T., Bertoletti, A., & Tan, A. T. (2010) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2010.01313.x · Cited by 94 · see citing works

Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality

Saha, A., O’Connor, R. S., Thangavelu, G., Lovitch, S. B., Dandamudi, D. B., Wilson, C. B., Vincent, B. G., Tkachev, V., Pawlicki, J. M., Furlan, S. N., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85796 · Cited by 91 · see citing works

T-Cell Suppression by Programmed Cell Death 1 Ligand 1 on Retinal Pigment Epithelium during Inflammatory Conditions

Sugita, S., Usui, Y., Horie, S., Futagami, Y., Aburatani, H., Okazaki, T., Honjo, T., Takeuchi, M., & Mochizuki, M. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2846 · Cited by 89 · see citing works

Conditional Deletion of Shp2 Tyrosine Phosphatase in Thymocytes Suppresses Both Pre-TCR and TCR Signals

Nguyen, T. V., Ke, Y., Zhang, E. E., & Feng, G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.5990 · Cited by 88 · see citing works

Adapter Function of Protein-tyrosine Phosphatase 1D in Insulin Receptor/Insulin Receptor Substrate-1 Interaction

Kharitonenkov, A., Schnekenburger, J., Chen, Z., Knyazev, P. G., Ali, S., Zwick, E., White, M. F., & Ullrich, A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.49.29189 · Cited by 75 · see citing works

Combination Checkpoint Blockade — Taking Melanoma Immunotherapy to the Next Level

Riley, J. L. (2013) · New England Journal of Medicine · doi:10.1056/nejme1305484 · Cited by 72 · see citing works

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

on behalf of the Cancer Immunotherapy Trials Network (CITN), Kohrt, H. E. K., Tumeh, P. C., Benson, D., Bhardwaj, N., Brody, J., Formenti, S. C., Fox, B. A., Galon, J., June, C. H., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0118-0 · Cited by 68 · see citing works

Trophoblast CD274 (B7-H1) Is Differentially Expressed Across Gestation: Influence of Oxygen Concentration1

Holets, L. M., Hunt, J. S., & Petroff, M. G. (2005) · Biology of Reproduction · doi:10.1095/biolreprod.105.046581 · Cited by 65 · see citing works

Dual Control of Antitumor CD8 T Cells through the Programmed Death-1/Programmed Death-Ligand 1 Pathway and Immunosuppressive CD4 T Cells: Regulation and Counterregulation

Currie, A. J., Prosser, A., McDonnell, A. M., Cleaver, A. L., Robinson, B. W. S., Freeman, G. J., & der Most, R. G. V. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901060 · Cited by 56 · see citing works

Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease

Karandikar, N. J., Vanderlugt, C. L., Bluestone, J. A., & Miller, S. D. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00058-7 · Cited by 55 · see citing works

LFA-1 is critical for regulatory T cell homeostasis and function

Wohler, J. E., Bullard, D. C., Schoeb, T. R., & Barnum, S. R. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.04.004 · Cited by 55 · see citing works

Differential Effects of Costimulatory Pathway Modulation on Corneal Allograft Survival

Watson, M. P., George, A. J. T., & Larkin, F. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-1597 · Cited by 53 · see citing works

Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.

Antonia, S. J., Goldberg, S. B., Balmanoukian, A. S., Sanborn, R. E., Steele, K. E., Narwal, R., Robbins, P. B., Gu, Y. L., Karakunnel, J. J., & Rizvi, N. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3014 · Cited by 47 · see citing works

CD4 + PD-1 + T Cells Acting as Regulatory Cells during the Induction of Anterior Chamber-Associated Immune Deviation

Meng, Q., Yang, P., Li, B., Zhou, H., Huang, X., Zhu, L., Ren, Y., & Kijlstra, A. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.06-0201 · Cited by 42 · see citing works

CD28 Costimulation Mediates Transcription of SKP2 and CKS1, the Substrate Recognition Components of SCFSkp2 Ubiquitin Ligase That Leads p27kip1 to Degradation

Appleman, L. J., Chernova, I., Li, L., & Boussiotis, V. A. (2006) · Cell Cycle · doi:10.4161/cc.5.18.3139 · Cited by 34 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Regulatory mechanisms of PD-1/PD-L1 in cancers

Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 850 · see citing works

Regulation of PD-L1 expression in the tumor microenvironment

Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681 · see citing works

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 543 · see citing works

The Role of Interleukin 6 During Viral Infections

Velázquez-Salinas, L., Verdugo-Rodríguez, A., Rodriguez, L. L., & Borca, M. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01057 · Cited by 488 · see citing works

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Wu, M., Huang, Q., Xie, Y., Wu, X., Ma, H., Zhang, Y., & Xia, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01242-2 · Cited by 471 · see citing works

Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities

Chen, L., Rong, D., Zhang, B., Zheng, W., Wang, X., Chen, Z., & Tang, W. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1047-6 · Cited by 416 · see citing works

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion

Gumber, D., & Wang, L. D. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103941 · Cited by 409 · see citing works

Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment

Zhao, Y., Shao, Q., & Peng, G. (2020) · Cellular &amp; Molecular Immunology · doi:10.1038/s41423-019-0344-8 · Cited by 382 · see citing works

Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts

Ziani, L., Chouaı̈b, S., & Thiery, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00414 · Cited by 379 · see citing works

The role of exosomal PD-L1 in tumor progression and immunotherapy

Xie, F., Xu, M., Lu, J., Mao, L., & Wang, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1074-3 · Cited by 354 · see citing works

IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy

Weber, R., Groth, C., Lasser, S., Arkhypov, I., Petrova, V., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104254 · Cited by 310 · see citing works

Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression

Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.017 · Cited by 292 · see citing works

Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment

Tsukamoto, H., Fujieda, K., Miyashita, A., Fukushima, S., Ikeda, T., Kubo, Y., Senju, S., Ihn, H., Nishimura, Y., & Oshiumi, H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0118 · Cited by 305 · see citing works

A snapshot of the PD-1/PD-L1 pathway

Ghosh, C., Luong, G., & Sun, Y. (2021) · Journal of Cancer · doi:10.7150/jca.57334 · Cited by 298 · see citing works

Resistance to Checkpoint Inhibition in Cancer Immunotherapy

Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 290 · see citing works

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade

Pang, K., Shi, Z., Wei, L., Yang, D. F., Ma, Y.-Y., Wang, W., Wang, G.-Y., Cao, M.-Y., Dong, J., Chen, Y.-A., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100907 · Cited by 265 · see citing works

FDG PET/CT for assessing tumour response to immunotherapy

Aide, N., Hicks, R. J., Tourneau, C. L., Lheureux, S., Fanti, S., & Lopci, E. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4171-4 · Cited by 262 · see citing works

Soluble immune checkpoints in cancer: production, function and biological significance

Gu, D., Ao, X., Yang, Y. P., Chen, Z., & Xu, X. M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0449-0 · Cited by 262 · see citing works

Progress and challenges of immunotherapy in triple-negative breast cancer

Zhu, Y., Zhu, X., Tang, C., Guan, X., & Zhang, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188593 · Cited by 237 · see citing works

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors

Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 240 · see citing works

Treg-mediated acquired resistance to immune checkpoint inhibitors

Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 238 · see citing works

Rheumatic immune-related adverse events from cancer immunotherapy

Calabrese, L. H., Calabrese, C. M., & Cappelli, L. C. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0074-9 · Cited by 233 · see citing works

PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model

Rosenzweig, N., Dvir-Szternfeld, R., Tsitsou-Kampeli, A., Keren‐Shaul, H., Ben-Yehuda, H., Weill-Raynal, P., Cahalon, L., Kertser, A., Baruch, K., Amit, I., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08352-5 · Cited by 223 · see citing works

Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma

Guo, X., Jiang, H., Shi, B., Zhou, M., Zhang, H., Shi, Z., Du, G., Luo, H., Wu, X., Wang, Y., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01118 · Cited by 206 · see citing works

Role of PD-1 in Immunity and Diseases

Chamoto, K., Al-Habsi, M., & Honjo, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_67 · Cited by 198 · see citing works

A comprehensive review of immune checkpoint inhibitors for cancer treatment

Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 196 · see citing works

Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1

Zhu, D., Xu, R., Huang, X., Tang, Z., Tian, Y., Zhang, J., & Zheng, X. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-00700-z · Cited by 179 · see citing works

Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade

Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 173 · see citing works

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study

Mo, H., Huang, J., Xu, J., Chen, X., Wu, D., Qu, D., Wang, X., Lan, B., Wang, X., Xu, J., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0100-3 · Cited by 153 · see citing works

&lt;p&gt;Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor&lt;/p&gt;

Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224013 · Cited by 153 · see citing works

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Chen, T. R., Wang, M., Chen, Y., & Liu, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03315-3 · Cited by 156 · see citing works

Not All Immune Checkpoints Are Created Equal

Linhares, A. D. S., Leitner, J. M., Grabmeier‐Pfistershammer, K., & Steinberger, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01909 · Cited by 147 · see citing works

Tumor-derived exosomes induce PD1+ macrophage population in human gastric cancer that promotes disease progression

Wang, F., Li, B., Wei, Y., Zhao, Y., Wang, L., Zhang, P., Yang, J., He, W., Chen, H., Jiao, Z., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0049-3 · Cited by 147 · see citing works

Prospects for combining immune checkpoint blockade with PARP inhibition

Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143 · see citing works

Advances in targeted therapy for malignant lymphoma

Wang, L., Qin, W. D., Huo, Y., Li, X., Shi, Q., Rasko, J. E. J., Janin, A., & Zhao, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0113-2 · Cited by 140 · see citing works

Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer

Vetsika, E.-K., Koukos, A., & Kotsakis, A. (2019) · Cells · doi:10.3390/cells8121647 · Cited by 125 · see citing works

Glioblastoma hijacks microglial gene expression to support tumor growth

Maas, S. L. N., Abels, E. R., van de Haar, L. L., Zhang, X., Morsett, L. M., Sil, S., Guedes, J. R., Sen, P., Prabhakar, S., Hickman, S. E., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01797-2 · Cited by 123 · see citing works

A Human IgSF Cell-Surface Interactome Reveals a Complex Network of Protein-Protein Interactions

Wojtowicz, W. M., Vielmetter, J., Fernandes, R. A., Siepe, D. H., Eastman, C., Chisholm, G. B., Cox, S. E., Klock, H. E., Anderson, P. W., Rue, S. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.025 · Cited by 118 · see citing works

Advances and perspectives of PARP inhibitors

Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S. (2019) · Experimental Hematology &amp; Oncology · doi:10.1186/s40164-019-0154-9 · Cited by 117 · see citing works

Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy

Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115 · see citing works

Gut microbiota-mediated immunomodulation in tumor

Liu, X., Chen, Y., Zhang, S., & Dong, L. (2021) · Journal of Experimental &amp; Clinical Cancer Research · doi:10.1186/s13046-021-01983-x · Cited by 112 · see citing works

Basis of PD1/PD-L1 Therapies

Seliger, B. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122168 · Cited by 110 · see citing works

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells

Saleh, R., Toor, S. M., Khalaf, S., & Elkord, E. (2019) · Vaccines · doi:10.3390/vaccines7040149 · Cited by 113 · see citing works

BRAF inhibitors: resistance and the promise of combination treatments for melanoma

Griffin, M., Scotto, D., Josephs, D. H., Mele, S., Crescioli, S., Bax, H. J., Pellizzari, G., Wynne, M. D., Nakamura, M., Hoffmann, R. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19836 · Cited by 112 · see citing works

Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells

Kim, N., & Kim, H. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02041 · Cited by 110 · see citing works

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer

Kok, V. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00268 · Cited by 104 · see citing works

Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice

Chen, Y., Pei, Y., Luo, J., Huang, Z., Yu, J., & Meng, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01088 · Cited by 102 · see citing works

Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer

Mediratta, K., El‐Sahli, S., D’Costa, V. M., & Wang, L. (2020) · Cancers · doi:10.3390/cancers12123529 · Cited by 102 · see citing works

Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer Agents

Cheng, B., Ren, Y., Niu, X., Wang, W., Wang, S., Tu, Y., Liu, S., Wang, J., Yang, D., Liao, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00574 · Cited by 102 · see citing works

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

Touchaei, A. Z., & Vahidi, S. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03293-6 · Cited by 102 · see citing works

Recent advances in small molecule based cancer immunotherapy

Cheng, B., Yuan, W., Su, J., Liu, Y., & Chen, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.028 · Cited by 100 · see citing works

Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review

Wang, N.-H., Lei, Z., Yang, H.-N., Tang, Z., Yang, M., Wang, Y., Sui, J.-D., & Wu, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6049 · Cited by 99 · see citing works

The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics

Abbasifard, M., & Khorramdelazad, H. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118097 · Cited by 99 · see citing works

Extremely Differentiated T Cell Subsets Contribute to Tissue Deterioration During Aging

Soto‐Heredero, G., Heras, M. M. G. D. L., Escrig-Larena, J. I., & Mittelbrunn, M. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-064501 · Cited by 97 · see citing works

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia

Yang, X., Ma, L., Zhang, X., Huang, L., & Wei, J. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00263-4 · Cited by 98 · see citing works

SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses

Christofides, A., Katopodi, X.-L., Cao, C., Karagkouni, D., Aliazis, K., Yenyuwadee, S., Aksoylar, H., Pal, R., Mahmoud, M. A. A., Strauss, L., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01385-x · Cited by 95 · see citing works

Emerging Role of PD-1 in the Central Nervous System and Brain Diseases

Zhao, J., Roberts, A., Wang, Z., Savage, J. T., & Ji, R. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00683-y · Cited by 93 · see citing works

Noncoding RNAs as potential mediators of resistance to cancer immunotherapy

Vishnubalaji, R., Shaath, H., Elango, R., & Alajez, N. M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.006 · Cited by 82 · see citing works

Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition

Siefker-Radtke, A. O., & Curti, B. D. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.190 · Cited by 82 · see citing works

Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy

van Gulijk, M., Dammeijer, F. F., Aerts, J. G. J. V., & Vroman, H. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02759 · Cited by 79 · see citing works

Malignant transformation of oral leukoplakia is associated with macrophage polarization

Weber, M., Wehrhan, F., Baran, C., Agaimy, A., Büttner-Herold, M. J., Öztürk, H., Neubauer, K., Wickenhauser, C., Kesting, M. R., & Ries, J. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-019-02191-0 · Cited by 79 · see citing works

Exploring immune checkpoints as potential therapeutic targets in atherosclerosis

Kusters, P. J. H., Lutgens, E., & Seijkens, T. T. P. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx248 · Cited by 80 · see citing works

Relevance of Regulatory T Cells during Colorectal Cancer Development

Olguín, J. E., Medina-Andrade, I., Rodríguez, T., Rodríguez‐Sosa, M., & Terrazas, L. I. (2020) · Cancers · doi:10.3390/cancers12071888 · Cited by 78 · see citing works

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies

Mhaidly, R., & Verhoeyen, E. (2020) · Cancers · doi:10.3390/cancers12071915 · Cited by 75 · see citing works

IL-10 Producing B Cells Ability to Induce Regulatory T Cells Is Maintained in Rheumatoid Arthritis

Mielle, J., Audo, R., Hahne, M., Macia, L., Combe, B. G., Morel, J., & Daïen, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00961 · Cited by 72 · see citing works

TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives

Yan, Z., Wang, C., Wu, J., Wang, J., & Ma, T. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00267-6 · Cited by 75 · see citing works

Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy

Yi, M., Jiao, D., Qin, S., Chu, Q., Li, A., & Wu, K. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419876351 · Cited by 69 · see citing works

Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer

Sun, F., Guo, Z. S., Gregory, A. D., Shapiro, S. D., Xiao, G., & Qu, Z. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000294 · Cited by 70 · see citing works

PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma

Rosenbaum, M. W., Gigliotti, B. J., Pai, S. I., Parangi, S., Wachtel, H., Mino-Kenudson, M. A., Gunda, V., & Faquin, W. C. (2018) · Endocrine Pathology · doi:10.1007/s12022-018-9514-y · Cited by 69 · see citing works

Tumor-derived exosomal HMGB1 promotes esophageal squamous cell carcinoma progression through inducing PD1+ TAM expansion

Li, B., Song, T., Wang, F., Yin, C., Li, Z., Lin, J.-P., Meng, Y., Feng, H., & Jing, T. (2019) · Oncogenesis · doi:10.1038/s41389-019-0126-2 · Cited by 69 · see citing works

SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer

Yigit, B., Wang, N., ten Hacken, E., Chen, S., Bhan, A. K., Suárez‐Fueyo, A., Katsuyama, E., Tsokos, G. C., Chiorazzi, N., Wu, C. J., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0664 · Cited by 69 · see citing works

Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients

Chen, P. P., Cepika, A., Agarwal, R., Saini, G., Uyeda, M. J., Louis, D. M., Cieniewicz, B., Narula, M., Amaya, L., Harre, N., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf5264 · Cited by 69 · see citing works

Lymph Node Lymphatic Endothelial Cell Expansion and Contraction and the Programming of the Immune Response

Lucas, E. D., & Tamburini, B. A. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00036 · Cited by 68 · see citing works

Programmed Cell Death-1/Programmed Cell Death Ligand-1 Checkpoint Inhibitors: Differences in Mechanism of Action

Zhang, N., Tu, J., Wang, X., & Chu, Q. (2019) · Immunotherapy · doi:10.2217/imt-2018-0110 · Cited by 66 · see citing works

Immune Checkpoint Molecules—Inherited Variations as Markers for Cancer Risk

Wagner, M., Jasek, M., & Karabon, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.606721 · Cited by 66 · see citing works

Targeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion

Yang, X., Huang, C., Zhong, M., Zhong, H., Ruan, R., Xiong, J., Yao, Y., Zhou, J., & Deng, J. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02033-1 · Cited by 61 · see citing works

Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC

Dong, Y., Wong, J. S. L., Sugimura, R., Lam, K. O., Li, B. K., Kwok, G. W., Leung, R. C.-Y., Chiu, J. W. Y., Cheung, T. T., & Yau, T. C. C. (2021) · Cancers · doi:10.3390/cancers13081949 · Cited by 59 · see citing works

Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy

Du, G., Dou, C., Sun, P., Wang, S., Liu, J., & Ma, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1431211 · Cited by 64 · see citing works

Establishing mechanisms affecting the individual response to ionizing radiation

Averbeck, D., Candéias, S. M., Chandna, S., Foray, N., Friedl, A. A., Haghdoost, S., Jeggo, P. A., Lumniczky, K., Paris, F., Quintens, R., et al. (2019) · International Journal of Radiation Biology · doi:10.1080/09553002.2019.1704908 · Cited by 60 · see citing works

XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients

Salama, E. A., Adbeltawab, R. E., & Tayebi, H. M. E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01459 · Cited by 60 · see citing works

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics

Abaza, A., Sid Idris, F., Anis Shaikh, H., Vahora, I., Moparthi, K. P., Al Rushaidi, M. T., Muddam, M. R., Obajeun, O. A., Jaramillo, A. P., & Khan, S. (2023) · Cureus · doi:10.7759/cureus.44582 · Cited by 59 · see citing works

PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications

Ortega, M. A., Boaru, D. L., León-Oliva, D. D., Fraile‐Μartinez, O., Montero, C. G., Rios, L., Garrido-Gil, M. J., Barrena-Blázquez, S., Minaya‐Bravo, A., Rios‐Parra, A., et al. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02463-3 · Cited by 62 · see citing works

Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy

Gutić, B., Božanović, T., Mandić, A., Dugalić, S., Todorović, J., Stanisavljevic, D. M., Gojnić-Dugalić, M., Şengül, D., Detanac, D. A., Şengül, İ., et al. (2023) · Clinics · doi:10.1016/j.clinsp.2023.100177 · Cited by 58 · see citing works

Y-Box Binding Protein 1: Unraveling the Multifaceted Role in Cancer Development and Therapeutic Potential

Dinh, N. T. M., Nguyen, T. M., Park, M. K., & Lee, C. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020717 · Cited by 58 · see citing works

Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations

AlDoughaim, M., Alsuhebany, N., Alzahrani, M., Alqahtani, T., Alghamdi, S. S., Badreldin, H. A., & Alshaykh, H. A. (2024) · Clinical Medicine Insights Oncology · doi:10.1177/11795549241298541 · Cited by 66 · see citing works

PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies

Frydenlund, N., & Mahalingam, M. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.06.012 · Cited by 58 · see citing works

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

Zhou, S., Khanal, S., & Zhang, H. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s193338 · Cited by 58 · see citing works

The role of exosomal PD-L1 in tumor immunotherapy

Wang, J., Zeng, H., Zhang, H., & Han, Y. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101047 · Cited by 58 · see citing works

Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report

Kopecký, J., Kubeček, O., Geryk, T., Slováčková, B., Hoffmann, P., Žiaran, M., & Priester, P. (2018) · Journal of Medical Case Reports · doi:10.1186/s13256-018-1786-9 · Cited by 57 · see citing works

Immunomodulatory aspects in the progression and treatment of oral malignancy

Kondoh, N., Mizuno‐Kamiya, M., Umemura, N., Takayama, E., Kawaki, H., Mitsudo, K., Muramatsu, Y., & Sumitomo, S. (2019) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2019.09.001 · Cited by 57 · see citing works

Design, Synthesis, and Biological Evaluation of Linear Aliphatic Amine-Linked Triaryl Derivatives as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction with Promising Antitumor Effects In Vivo

Guo, J., Luo, L., Wang, Z., Hu, N., Wang, W., Xie, F., Liang, E., Yan, X., Xiao, J., & Li, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01329 · Cited by 56 · see citing works

The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers

Compérat, É., Amin, M. B., Epstein, J. I., Hansel, D. E., Paner, G. P., Al‐Ahmadie, H. A., True, L., Bayder, D., Bivalacqua, T. J., Brimo, F., et al. (2021) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000309 · Cited by 56 · see citing works

Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors

Reul, J., Frisch, J., Engeland, C. E., Thalheimer, F. B., Hartmann, J., Ungerechts, G., & Buchholz, C. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00052 · Cited by 56 · see citing works

T cell exhaustion in cancer: Mechanisms and clinical implications

Wang, J., Xu, Y., Huang, Z., & Lu, X. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26645 · Cited by 54 · see citing works

Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts

Sugawara, E., Kato, M., Kudo, Y., Lee, W. S., Hisada, R., Fujieda, Y., Oku, K., Bohgaki, T., Amengual, O., Yasuda, S., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1664144 · Cited by 53 · see citing works

Immune cellular components and signaling pathways in the tumor microenvironment

Yenyuwadee, S., Aliazis, K., Wang, Q., Christofides, A., Shah, R., Patsoukis, N., & Boussiotis, V. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.004 · Cited by 54 · see citing works

Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity

Zhang, J.-C., Chen, W., Alvarez, J. B., Jia, K. Q., Shi, L., Wang, Q., Zou, N., He, K., & Hua Zhu, C. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0062-2 · Cited by 54 · see citing works

PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients

Wu, D., Liu, Y., Pang, N., Sun, M., Wang, X., Haridia, Y., Zhao, F., Qin, Y., Fan, W., Guo, X., et al. (2019) · Medicine · doi:10.1097/md.0000000000017608 · Cited by 53 · see citing works

The Role of B7 Family Molecules in Maternal–Fetal Immunity

Zhao, Y., Zheng, Q., & Jin, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00458 · Cited by 52 · see citing works

Biochemical Signaling of PD-1 on T Cells and Its Functional Implications

Boussiotis, V. A., Chatterjee, P., & Li, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000059 · Cited by 186 · see citing works

The role of the PD‐1 pathway in autoimmunity and peripheral tolerance

Fife, B. T., & Pauken, K. E. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05919.x · Cited by 355 · see citing works

Role of PD-1 in Regulating T-Cell Immunity

Jin, H., Ahmed, R., & Okazaki, T. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_116 · Cited by 303 · see citing works

The PD‐1 pathway in tolerance and autoimmunity

Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300 · see citing works

PD-1 and Its Ligands in Tolerance and Immunity

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works